Ever more germane to the studies, however, is the worm's very well characterized central nervous system. elegans has all the physiological properties of an animal, the ability to replicate human diseases and also has a fast life cycle, making it a highly desirable animal model for Phase 2 bio-assays. Christian Griñán Ferré, from University of Barcelona (the " Investigators") and studies have now been designed to conduct Phase 2 in vivo (within living organisms) bio-assay studies, which will comprise the incorporation of the nematode (worm) Caenorhabditis elegans (" C. Leading from the success of Phase 1 studies, commitment has been received from Dr. Results from Phase 1 bioassay studies were very encouraging, indicating that the bio-compounds alone have a strong potential to induce beneficial effects. Part of Akome's phase one (" Phase 1") studies included bioassay studies conducted by Neuro-Zone Srl, (" Neuro-Zone") (see Company press release dated April 2, 2022), Fundación Medina (Granada, Spain) and Universidad Complutense (Madrid, Spain), aiming to confirm central nervous system activity of the specific plant bio-compounds covered in Akome's various United States Patent and Trademark Office (USPTO) patent submissions and underlying neuropathological mechanisms related to the targeted diseases. The studies are the next step of Akome's pre-clinical development of novel psychedelic drug alternatives for the treatment of various neurological disorders, such as Alzheimer Disease (" Alzheimer's"), Parkinson's Disease (" Parkinson's"), Ischemic Stroke (" Stroke") and Depression, (collectively the " Targeted Diseases"). (" Akome") has finalized study parameters and signed a contract with Fundació Bosh I Gimpera, in representation of Universitat de Barcelona (the " University of Barcelona"), to commence the second phase (" Phase 2") studies to evaluate the therapeutic potential of its bio-compounds, alone and in combination with various psychedelic compounds, on the central nervous system. (CSE: COOL)(OTCQB: CLABF)(Frankfurt: LD6)(WKN: A3CSSU) (the " Company" or " Core One"), in follow-up to its press release dated September 16, 2022, is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. VANCOUVER, BC / ACCESSWIRE / Janu/ Core One Labs Inc.
0 Comments
Leave a Reply. |